KW-2478 is a novel non-ansamycin potent Hsp90 inhibitor with an IC50 of 3.8 nM. KW-2478 is a novel non-purine analogue antagonist for Hsp90. KW-2478 suppressed the binding of bRD to HSP90α in concentration-dependent manner. KW-2478 indicated a potent anti-cancer activity both in vitro and in vivo. KW-2478 clearly prevented cancer cell growth in all cell lines, with EC50 of 101-252, 81.4-91.4 and 120-622 nM for B-cell lymphoma, mantle cell lymphoma and multiple myeloma, respectively. KW-2478 also showd potent growth inhibitory activity in primary CLL (n=3) and NHL (n=2) cells with EC50 of 40-170 nM and 200-400 nM, respectively. KW-2478 depleted the Hsp90 client Cdk9, a transcriptional kinase, and the phosphorylated 4E-BP1, a translational inhibitor. Both inhibitory effects of KW-2478 on such transcriptional and translational pathways were shown to reduce c-Maf and cyclin D1 expression. In NCI-H929 s.c. inoculated model, KW-2478 displayed a significant inhibition of tumor growth and induced the degradation of client proteins in tumors.
|Cell lines||OPM-2/GFP, KMS-11, RPMI 8226, and NCI-H929 cells|
|Preparation method||To measure the IC50, plating OPM-2/green fluorescent protein (GFP) cells, KMS-11 cells, OPM-2/GFP and other cells into 96-well plates and treating them with KW-2478. 72 hours of cultivation later, using Cell Proliferation Reagent WST-1 to determine cell viability . WST reagent is added to the wells, followed by incubation for 4 hours at 37 °C. After that, measuring the absorbance at 450 nm with reference at 650 nm with a microplate spectrophotometer. To examine time dependency of antiproliferative activity of KW-2478, plating the cells into 96-well V-bottomed plates and treating with KW-2478. After 0 hour and at intervals from 3 to 72 hours at 37 °C, the supernatant is aspirated. After drug-free medium is added to the wells, the supernatant is aspirated again. Finally, adding drug-free medium to the wells, and the plates are further incubated for the remainder of the 72-hour period, followed by measurement of cell viabil|
|Concentrations||0.05 - 5 μM|
|Incubation time||3 days|
|Animal models||NCI-H929 tumors s.c. inoculated in SCID mice, OPM-2/GFP i.v. inoculated mouse model|
|Formulation||sterile 0.9% sodium chloride solution|
|Dosages||25, 50 , 100 and 200 mg/kg|
|Administration||Orally administrated once daily for 5 days|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 100 mg/mL|
|Related HSP90 Products|
Teprenone(Geranylgeranylacetone; GGA)is commonly utilized to protect the gastric mucosa in peptic ulcer disease; has been shown to protect the myocardium from ischemia/reperfusion by activating heat shock proteins.
Celastrol is a potent antioxidant and anti-inflammatory agent and a novel HSP90 inhibitor.
CH5138303 is an orally available Hsp90 inhibitor with Kd of 0.48 nM.
Retaspimycin is a novel, water-soluble, potent inhibitor of heat-shock protein 90 (Hsp90).
Geldanamycin is a natural existing HSP90 inhibitor with Kd of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.